188 related articles for article (PubMed ID: 38610996)
1. Radiomodulating Properties of Superparamagnetic Iron Oxide Nanoparticle (SPION) Agent Ferumoxytol on Human Monocytes: Implications for MRI-Guided Liver Radiotherapy.
Shurin MR; Kirichenko VA; Shurin GV; Lee D; Crane C; Kirichenko AV
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610996
[TBL] [Abstract][Full Text] [Related]
2. Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance-based detection in vivo.
Sharkey J; Starkey Lewis PJ; Barrow M; Alwahsh SM; Noble J; Livingstone E; Lennen RJ; Jansen MA; Carrion JG; Liptrott N; Forbes S; Adams DJ; Chadwick AE; Forbes SJ; Murray P; Rosseinsky MJ; Goldring CE; Park BK
Cytotherapy; 2017 Apr; 19(4):555-569. PubMed ID: 28214127
[TBL] [Abstract][Full Text] [Related]
3. Impact of Superparamagnetic Iron Oxide Nanoparticles on THP-1 Monocytes and Monocyte-Derived Macrophages.
Polasky C; Studt T; Steuer AK; Loyal K; Lüdtke-Buzug K; Bruchhage KL; Pries R
Front Mol Biosci; 2022; 9():811116. PubMed ID: 35211509
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Ferumoxytol as a Breast Cancer-Associated Macrophage Tracer with Five-Dimensional Quantitative [Fe]MRI of SPION Dynamics.
Sillerud LO; Neuwelt AJ; Staquicini FI; Arap W; Pasqualini R
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359704
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of Iron Oxide-Based Contrast Agents in Rabbit Atherosclerotic Plaques in Relation to Plaque Age and Vulnerability Features.
Sekita A; Unterweger H; Berg S; Ohlmeyer S; Bäuerle T; Zheng KH; Coolen BF; Nederveen AJ; Cabella C; Rossi S; Stroes ESG; Alexiou C; Lyer S; Cicha I
Int J Nanomedicine; 2024; 19():1645-1666. PubMed ID: 38406599
[TBL] [Abstract][Full Text] [Related]
6. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
Evans RJ; Lavin B; Phinikaridou A; Chooi KY; Mohri Z; Wong E; Boyle JJ; Krams R; Botnar R; Long NJ
Nanotheranostics; 2020; 4(4):184-194. PubMed ID: 32637296
[No Abstract] [Full Text] [Related]
7. Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors.
Li M; Kim HS; Tian L; Yu MK; Jon S; Moon WK
Theranostics; 2012; 2(1):76-85. PubMed ID: 22272221
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility of Dextran-Coated 30 nm and 80 nm Sized SPIONs towards Monocytes, Dendritic Cells and Lymphocytes.
Zschiesche L; Janko C; Friedrich B; Frey B; Band J; Lyer S; Alexiou C; Unterweger H
Nanomaterials (Basel); 2022 Dec; 13(1):. PubMed ID: 36615924
[TBL] [Abstract][Full Text] [Related]
9. Superparamagnetic iron oxide nanoparticles impair endothelial integrity and inhibit nitric oxide production.
Astanina K; Simon Y; Cavelius C; Petry S; Kraegeloh A; Kiemer AK
Acta Biomater; 2014 Nov; 10(11):4896-4911. PubMed ID: 25123083
[TBL] [Abstract][Full Text] [Related]
10. Shell matters: Magnetic targeting of SPIONs and in vitro effects on endothelial and monocytic cell function.
Matuszak J; Dörfler P; Zaloga J; Unterweger H; Lyer S; Dietel B; Alexiou C; Cicha I
Clin Hemorheol Microcirc; 2015; 61(2):259-77. PubMed ID: 26410877
[TBL] [Abstract][Full Text] [Related]
11. Superparamagnetic iron oxide nanoparticle uptake alters M2 macrophage phenotype, iron metabolism, migration and invasion.
Rojas JM; Sanz-Ortega L; Mulens-Arias V; Gutiérrez L; Pérez-Yagüe S; Barber DF
Nanomedicine; 2016 May; 12(4):1127-1138. PubMed ID: 26733263
[TBL] [Abstract][Full Text] [Related]
12. Quantifying Liver Heterogeneity via R2*-MRI with Super-Paramagnetic Iron Oxide Nanoparticles (SPION) to Characterize Liver Function and Tumor.
Lee D; Sohn J; Kirichenko A
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358689
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the effects of dexamethasone treatment by MRI using in vivo iron oxide nanoparticle-labeled macrophages.
Gramoun A; Crowe LA; Maurizi L; Wirth W; Tobalem F; Grosdemange K; Coullerez G; Eckstein F; Koenders MI; Van den Berg WB; Hofmann H; Vallée JP
Arthritis Res Ther; 2014 Jun; 16(3):R131. PubMed ID: 24957862
[TBL] [Abstract][Full Text] [Related]
14. Emerging applications for ferumoxytol as a contrast agent in MRI.
Bashir MR; Bhatti L; Marin D; Nelson RC
J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of LA-PEG-SPION, a targeted MRI contrast agent for liver cancer.
Xia L; Song X; Yan G; Quan J; Jin G
Open Life Sci; 2022; 17(1):952-959. PubMed ID: 36045712
[TBL] [Abstract][Full Text] [Related]
16. Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II.
Wang G; Serkova NJ; Groman EV; Scheinman RI; Simberg D
Mol Pharm; 2019 Oct; 16(10):4274-4281. PubMed ID: 31556296
[TBL] [Abstract][Full Text] [Related]
17. pH-responsive pHLIP (pH low insertion peptide) nanoclusters of superparamagnetic iron oxide nanoparticles as a tumor-selective MRI contrast agent.
Wei Y; Liao R; Mahmood AA; Xu H; Zhou Q
Acta Biomater; 2017 Jun; 55():194-203. PubMed ID: 28363789
[TBL] [Abstract][Full Text] [Related]
18. Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety.
Unterweger H; Dézsi L; Matuszak J; Janko C; Poettler M; Jordan J; Bäuerle T; Szebeni J; Fey T; Boccaccini AR; Alexiou C; Cicha I
Int J Nanomedicine; 2018; 13():1899-1915. PubMed ID: 29636608
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
